Abstract
Objective
To evaluate the safety and efficacy of tirofiban in high risk patients with non‐ST‐segment elevation acute coronary syndromes (NSTE‐ACS) after percutaneous coronary intervention (PCI).
Methods
A total of 240 patients were randomized to either a tirofiban group or a control group.
Results
Compared with the control group, the platelet aggregation rate in the tirofiban group was lower (P < 0.01); the plasma levels of CK‐MB and troponin I, cardiac form (cTnI) were lower (P < 0.05); ECG improved significantly (P < 0.05); the incidence of major adverse cardiac events (MACE) was lower (P < 0.05); and there was no difference in bleeding complications between the 2 groups (P = 0.1).
Conclusions
The administration of tirofiban in high risk patients with NSTE‐ACS after PCI is safe and effective. Copyright © 2009 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (105.5 KB).
References
- 1. Hartman GD. Tirofiban hydrochloride: platelet antiaggregatory GP IIb/IIIa receptor antagonist. Drugs Future 1995; 20: 897–901. [Google Scholar]
- 2. Madan M, Berkawitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation 1998; 98: 2629–2635. [DOI] [PubMed] [Google Scholar]
- 3. Lynch JJ, Cook JJ, Sitko GR, et al. Nonpeptide glycoprotein IIb/IIIa inhibitors. Antithrombotic effects of MK‐0383. J Pharmacol Exp Ther 1995; 272: 20–32. [PubMed] [Google Scholar]
- 4. The PRISM Study Investigators . A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498–1505. [DOI] [PubMed] [Google Scholar]
- 5. PRISM‐PLUS Study Investigators . Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non‐Q‐wave myocardial infarction. N Engl J Med 1998; 338: 1488–1497. [DOI] [PubMed] [Google Scholar]
- 6. RESTORE Investigators . Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96(5): 1445–1453. [DOI] [PubMed] [Google Scholar]
- 7. Okmen E, Sanli A, Uyarel H, Dayi S, Tartan Z, Cam N. Effects of glycoprotein IIb/IIIa receptor inhibition with tirofiban on minor myocardial damage in angiographically successful percutaneous coronary angioplasty. Cardiology 2004; 102: 18–23. [DOI] [PubMed] [Google Scholar]
- 8. Zhang Q, Zhang RY, Zhang JS, et al. One‐year clinical outcomes of Chinese sirolimus‐eluting stent in the treatment of unselected patients with coronary artery disease. Chin Med J (Engl) 2006; 119: 165–168. [PubMed] [Google Scholar]
- 9. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992; 19: 926–935. [DOI] [PubMed] [Google Scholar]
- 10. Willerson JT. Inhibitors of platelet glycoprotein IIb/IIIa receptors: will they be useful when given chronically? Circulation 1996; 94: 866–868. [DOI] [PubMed] [Google Scholar]
- 11. Danzi GB, Capuano C, Migliorini A, Sesana M, Baglini R, Antoniucci D. Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention. Curr Med Opin 2003; 19: 28–33. [DOI] [PubMed] [Google Scholar]
- 12. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus‐eluting stent vs abciximab and bare‐metal stent for acute myocardial infarction:a randomized trial. JAMA 2005; 293: 2109–2117. [DOI] [PubMed] [Google Scholar]
- 13. Teirstein PS, Kao J, Watkins M, et al. Impact of platelet glycoprotein IIb/IIIa inhibition on the paclitaxel‐eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy). Am J Cardiol 2005; 96(4): 500–505. [DOI] [PubMed] [Google Scholar]
- 14. Braunwald E, Antman E, Beasley J, et al. ACC/AHA guidelines for the management of patients with unstable angina and non‐ST‐segment elevation myocardial infarction. J Am Coll Cardiol 2000; 36(3): 970–1062. [DOI] [PubMed] [Google Scholar]
- 15. De Queiroz Fernandes Arau JO, Veloso HH, Braga De Paiva JM, Filho MW, Vincenzo De Paola AA. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: A meta analysis of randomized, controlled trials. Am Heart J 2004; 148: 937–943. [DOI] [PubMed] [Google Scholar]
- 16. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST‐segment elevation myocardial infarction: a meta‐analysis. JAMA 2004; 292: 362–366. [DOI] [PubMed] [Google Scholar]
- 17. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non‐ST‐Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non‐ST‐Elevation Myocardial Infarction) . Circulation. 2007;116:e148–e304. [DOI] [PubMed]
- 18. Guidelines for the diagnosis and treatment of non‐ST‐segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non‐ST‐Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J. 2007; 28:1598–1660. [DOI] [PubMed]